INFLEXIÓNin the comprehensive approach to DM2

project
project
project
project
project
project
project

Challenge​

The extensive therapeutic arsenal available for the treatment of diabetes and its close relationship with cardiovascular risk and kidney disease has generated the appearance of numerous studies. The results have shown the disposal of safe drugs and easy to use, displaying a reduction in the hospitalization for heart failure and a slowing down the deterioration of renal function, moving towards the positioning of said drug moiety in primary prevention.

Given these results, a change was necessary in the clinician's perception of the need to optimize treatment in diabetic patients, not only in secondary prevention, but also in cases where there is no established cardiovascular disease, but other factors of cardiovascular risk.

Solution​​

We were looking for an umbrella concept that would convey a change in trend, a key point in optimizing the preventive treatment of diabetes. As an expression of these ideas, Inflection emerged. A concept that refers us both to the results of the study and to the launch of the drug.

Under this main concept, we carry out training aimed at the doctors involved in the management of diabetic patients. This consisted of five national meetings in train the trainers' format, which had keynote talks by experts, and workshops, as dynamics, to work on the contents learned, giving answers to the interpretation of the study, and answering the key questions in the treatment of DM2.

Subsequently, a Meeting in a box was delivered with the presentations of the papers and the resolved hot questions, for the subsequent dissemination of content in local meetings.

Results​

Thanks to this update, a large number of professionals delved into the importance of primary and secondary prevention of cardiovascular and renal risk in DM2, knowing the parameters and factors that must be taken into account when planning treatment, analyzing the needs and barriers to a comprehensive approach to these patients, and, therefore, improving routine clinical practice in patients who are candidates for these drugs.